Archives
- o2h Ventures, Third-Time Finalist in the Best EIS Manager Specialist at the Growth Investor Awards 2024 09 August, 2024
- Proud Partner of the 30th Anniversary Event by EISA, celebrating three decades of Enterprise Investment Schemes (EIS) 06 August, 2024
- From Biotech Chemist to Family Office to Biotech Pioneer – Sunil Shah’s Exciting Journey in Biotech 31 July, 2024
- o2h Ventures Proud to be Shortlisted for the EISA Impact Award for a Second Year Running! 07 June, 2024
- o2h Ventures Announces Seed Investment in AscendBio, A Company Advancing Therapies for Metabolic and Respiratory Diseases 03 May, 2024
- o2h Ventures Invests in Vesynta, a Company Developing an AI Software to Maximise Therapeutic Potential and De-risk drug development 23 April, 2024
- o2h Ventures invests in ClotProtect, a Company Developing Treatment to Improve Bleeding and Survival Outcomes 22 April, 2024
- o2h Ventures Invests in Stratosvir – Advancing Viral Immunotherapy For Late-Stage Cancer 17 April, 2024
- o2h Ventures Announces SEIS Investment in Innovative mRNA-Based Hearing Loss Treatment Company, CamGene Therapeutics 05 April, 2024
invest in the growth potential of UK life science & AI